Related Experiment Video
Updated: May 24, 2026

Adapted Resistance Training Improves Strength in Eight Weeks in Individuals with Multiple Sclerosis
Published on: January 29, 2016
Fourteen years in resistance
1Norwich Medical School, University of East Anglia, Norwich NR4 7TJ, UK. d.livermore@uea.ac.uk
Abstract:
Resistance trends have changed greatly over the 14 years (1997-2011) whilst I was Director of the UK Antibiotic Resistance Monitoring and Reference Laboratory (ARMRL). Meticillin-resistant Staphylococcus aureus (MRSA) first rose, then fell with improved infection control, although with the decline of one major clone beginning before these improvements. Resistant pneumococci too have declined following conjugate vaccine deployment. If the situation against Gram-positive pathogens has improved, that against Gram-negatives has worsened, with the spread of (i) quinolone- and cephalosporin-resistant Enterobacteriaceae, (ii) Acinetobacter with OXA carbapenemases, (iii) Enterobacteriaceae with biochemically diverse carbapenemases and (iv) gonococci resistant to fluoroquinolones and, latterly, cefixime. Laboratory, clinical and commercial aspects have also changed. Susceptibility testing is more standardised, with pharmacodynamic breakpoints. Treatments regimens are more driven by guidelines. The industry has fewer big profitable companies and more small companies without sales income. There is good and bad here. The quality of routine susceptibility testing has improved, but its speed has not. Pharmacodynamics adds science, but over-optimism has led to poor dose selection in several trials. Guidelines discourage poor therapy but concentrate selection onto a diminishing range of antibiotics, threatening their utility. Small companies are more nimble, but less resilient. Last, more than anything, the world has changed, with the rise of India and China, which account for 33% of the world's population and increasingly provide sophisticated health care, but also have huge resistance problems. These shifts present huge challenges for the future of chemotherapy and for the edifice of modern medicine that depends upon it.
Insights
Antibiotic resistance trends show declining Gram-positive infections like MRSA and pneumococci, but worsening Gram-negative resistance, particularly in Enterobacteriaceae and Acinetobacter. Global shifts and industry changes pose future challenges.
Area of Science:
- Medical Microbiology
- Infectious Diseases
- Public Health
Background:
- Over 14 years (1997-2011), significant shifts in antibiotic resistance trends were observed.
- Improvements in infection control and vaccine deployment impacted resistance patterns for Gram-positive pathogens.
- Emergence and spread of multidrug-resistant Gram-negative bacteria present a growing concern.
Purpose of the Study:
- To analyze the changing landscape of antibiotic resistance trends in the UK.
- To evaluate the impact of interventions, laboratory advancements, and global factors on resistance.
- To identify future challenges for antibiotic chemotherapy and modern medicine.
Main Methods:
- Longitudinal analysis of antibiotic resistance data from 1997-2011.
- Monitoring of key pathogens including meticillin-resistant Staphylococcus aureus (MRSA), resistant pneumococci, Enterobacteriaceae, Acinetobacter, and gonococci.
- Assessment of changes in laboratory practices, clinical guidelines, and the pharmaceutical industry.
Main Results:
- Meticillin-resistant Staphylococcus aureus (MRSA) and resistant pneumococci showed declines.
- Significant increases in resistance were noted for Gram-negative bacteria, including quinolone- and cephalosporin-resistant Enterobacteriaceae, carbapenemase-producing Acinetobacter and Enterobacteriaceae, and fluoroquinolone/cefixime-resistant gonococci.
- Laboratory testing improved in standardization but not speed; pharmacodynamic breakpoints added scientific rigor but led to some dosing issues.
Conclusions:
- While Gram-positive resistance has improved, Gram-negative resistance poses a severe and escalating threat.
- Changes in the pharmaceutical industry and global health dynamics, particularly the rise of India and China, present complex challenges.
- The future of antibiotic chemotherapy and modern medicine is threatened by these evolving resistance patterns and global factors.
Related Concept Videos
Resistance
The Stanford Prison Experiment
Resistance and Conductance
Various factors impact the resistance of a conductor. Spiraling in stranded conductors increases their length...
Repressed Memory
Milgram's Obedience to Authority
Resistors In Parallel

